Comparison of outcome after first - line chemotherapy treatment in types of KRAS mutated lung cancer

Abstract

BACKGROUND: As suggested by in-vitro data, we hypothesize that subtypes of KRAS mutated

6 Figures and Tables

Cite this paper

@inproceedings{Mellema2016ComparisonOO, title={Comparison of outcome after first - line chemotherapy treatment in types of KRAS mutated lung cancer}, author={Wouter W. Mellema and Lucie J P Masen-Poos and Egbert F. Smit and Lizza E.L. Hendriks and Joachim G. J. V. Aerts and Arien Termeer and Martijn J. Goosens and Hans J. M. Smit and Michel M. van den Heuvel and A J van der Wekken and Gerarda J. M. Herder and Frans H. Krouwels and Jos A. Stigt and Tjeerd J. Haitjema and Agnes J. Staal-Van den Brekel and Robbert C. van Heemst and Ellen Pouw and A. M. Dingemans}, year={2016} }